No of women | % (95% CI) | |
Total | 986 | 26.7 (25.3 to 28.1) |
Composite indicator of moderate to severe infection | 144 | 14.6 (12.5 to 17.0) |
Oxygen saturation measured on admission (yes) | 857 | 86.9 (84.7 to 88.9) |
Oxygen saturation <95% | 31 | 4.2 (2.9 to 5.9) |
Evidence of pneumonia on imaging | 72 | 7.3 (5.8 to 9.1) |
Respiratory support required:* | 99 | 10.4 (8.6 to 12.5) |
Non-invasive oxygen (nasal canulae, mask, or non-rebreathe mask at <15 L/min) | 71 | 78.9 (69.3 to 86.1) |
High flow nasal oxygen (≥15 L/min) or CPAP | 7 | 7.8 (3.6 to 15.4) |
Invasive ventilation or ECMO | 12 | 13.3 (6.1 to 27.6) |
Level not known | 9 | |
Intensive care unit admission | 30 | 3.0 (2.1 to 4.3) |
Maternal death | 4 | 0.4 (0.1 to 1.1) |
Pharmacological management total: | 50 | 5.1 (3.9 to 6.6) |
Antivirals | 3 | 0.3 (0.1 to 0.9) |
Tocilizumab | 9 | 0.9 (0.5 to 1.8) |
Corticosteroids for maternal indication | 43 | 4.4 (3.2 to 5.8) |
Monoclonal antibodies | 6 | 0.6 (0.3 to 1.4) |
Recruited to RECOVERY trial | 5 | 0.5 (0.2 to 1.2) |
CPAP=continuous positive airway pressure; ECMO=extracorporeal membrane oxygenation; CI=confidence interval.
*Information about need for respiratory support was available for 953 women.
†Any of the listed medications given for medical management of SARS-CoV-2: antivirals, tocilizumab, maternal corticosteroids, and monoclonal antibodies.